维普期刊资源整合服务平台（V6.5）

1176篇 您的检索式：期刊名="Clin Breast Cancer"

选中清除导出查看参考文献查看引证文献引用追踪共59页首页上一页第1页下一页末页 /59 跳转

	题名	作者	年代	出处	被引量
1	Bisphosphonates:biological response modifiers in breast cancer显示文摘	Tom Baker	2002	Clin Breast Cancer2002，3，3：	2
2	Platinum compounds in the treatment of advanced breast cancer显示文摘	Martin M	2001	Clin Breast Cancer2001，2，3：	1
3	The HER2 extracellular domain as a prognostic and predictive factor in breast cancer 显示文摘	Harris L	2002	Clin Breast Cancer2002，3，2：	1
4	HER2-Positive Breast Cancer: Update on Breast Cancer International Research Group Trials 显示文摘	Nabhohz JM Reese DM Eindsay MA	2002	Clin Breast Cancer2002，2，：	1
5	E21100:a phase Ⅲ trial ofpaclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer显示文摘	Miller KD	2003	Clin Breast Cancer2003，3，6：	1
6	Pemetrexed(Alimta)and gemcitabine in breast cancer patients previously treated with anthracycilnes and taxanes显示文摘	Adjei A	2002	Clin Breast Cancer2002，3，1：	1
7	The global breast cancer burden:variations in epidemio- logy and survival显示文摘	HORTOBAGYI G N DE LA GARZA S J PRITCHARD K	2005	Clin Breast Cancer2005，6，5：	1
8	Phase H study of neoadjuvant weekly nab-paelitaxel and carboplatin, with bevaci- zumab and trastuzumab, as treatment for women with locally ad- vanced HER2 + breast cancer显示文摘	Yardley DA Raefsky E Castillo R	2011	Clin Breast Cancer2011，11，5：	1
9	Phase 1I trial ff nab-paclitaxel compared with docetaxel as first- line chemotherapy in patients with metastatic breast cancer: final analysis of overall sut'ival显示文摘	GRADISHAR WJ KRASNOJON D CHEPOROV S	2012	Clin Breast Cancer2012，12，5：	1
10	Ixabepilone,first in a new class of antineoplastic agents:the natural epothilones and their analogues显示文摘	Fornier M	2007	Clin Breast Cancer2007，7，10：	1
11	Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer:association with lymph node metastasis显示文摘	Koyama Y Kaneko K Akazawa K	2003	Clin Breast Cancer2003，4，5：	1
12	Bisphosphonates: Biological response modifiers in breast cancer 显示文摘	Paterson AH	2002	Clin Breast Cancer2002，3，3：	1
13	Current status of anti- human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance 显示文摘	Chung A Cui X Audeh W	2013	Clin Breast Cancer2013，13，4：	1
14	Treatment and outcomes of primary breast lymphoma显示文摘	Caon J Wai E S Hart J	2012	Clin Breast Cancer2012，12，6：	1
15	Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer显示文摘	Ademuyiwa FO Miller KD	2008	Clin Breast Cancer2008，8，4：	1
16	Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer 显示文摘	Andreopoulou E Gaiotti D Kim E	2007	Clin Breast Cancer2007，7，9：	1
17	Urekinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer 显示文摘	HARBECK N KATES R E SCHMITr M	2004	Clin Breast Cancer2004，5，5：	1
18	Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade显示文摘	Gajdos C Jordan VC	2002	Clin Breast Cancer2002，2，4：	1
19	Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials显示文摘	Ross PJ Powles TJ	2001	Clin Breast Cancer2001，2，1：	1
20	Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of pa- tients with advanced breast cancer: a phase 11, randomized, open-label trial 显示文摘	Robert NJ Saleh MN Paul D	2011	Clin Breast Cancer2011，11，2：	1

返回顶部每页显示：

共59页首页上一页第1页下一页末页 /59 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示